Fidelity Investments’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Fidelity Investments’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Hold	0	–	-$4	–	5787
2023 Q4	–	Sell	-3	Closed	-$1.48K	–	5383
2023 Q3	$2.23K	Hold	3	–	–	﹤0.01%	4517
2023 Q2	$15.8K	Buy	3 +2	+200%	+$6.94K	﹤0.01%	3967
2023 Q1	$1.43K	Hold	1	–	–	﹤0.01%	4695
2022 Q4	$2.45K	Hold	1	–	–	﹤0.01%	4458
2022 Q3	$3K	Hold	1	–	–	﹤0.01%	4501
2022 Q2	$2K	Buy	+1	New	+$2.6K	﹤0.01%	4623
2022 Q1	–	Hold	0	–	–	–	4728
2021 Q3	–	Hold	0	–	–	–	5161
2021 Q2	–	Hold	0	–	–	–	5005

Other funds holding SEEL

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFWC

Strategic Family Wealth Counselors Fairfield, New Jersey $381M AUM 21.36% 1-Year Est. Return

Fidelity Investments's SEEL Position: Q1 2024 in Review

Fidelity Investments held its Seelos Therapeutics, Inc. Common Stock (SEEL) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5787.

Fidelity Investments first reported a position in SEEL in Q2 2022 and has held it in 6 quarters since. The position peaked at $15.8K in Q2 2023. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

Fidelity Investments held 0 shares of Seelos Therapeutics, Inc. Common Stock worth $0 as of Q1 2024.
Fidelity Investments left its Seelos Therapeutics, Inc. Common Stock share count unchanged in Q1 2024.
Seelos Therapeutics, Inc. Common Stock made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2024, its #5787 holding.
Fidelity Investments first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2022 and has held it in 6 quarters since.
Fidelity Investments's Seelos Therapeutics, Inc. Common Stock position peaked at $15.8K in Q2 2023.
29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Fidelity Investments's 13F filing for Q1 2024, filed 13 May 2024.